NEWEarnings

Allogene Therapeutics (ALLO) reports interim Phase 2 trial results

Published on 4/13/2026

#ALLO#oncology#clinicaltrials
Allogene Therapeutics (ALLO) reports interim Phase 2 trial results

AI Summary

Allogene Therapeutics (ALLO) announced interim results from its Phase 2 ALPHA3 trial for cema-cel in lymphoma. The trial aimed to evaluate the efficacy and safety of the therapy. Key findings from the trial include specific responses in patient outcomes, though numbers were not disclosed in the announcement. The results could influence market sentiment regarding ALLO's future performance and the potential for cema-cel as a treatment option in oncology.

Source: Read original article (opens in new tab)

Related News

Goldman Sachs (GS) Reports Q1 Earnings: $17.55 EPS, $17.23B Revenue
Earnings

Goldman Sachs (GS) Reports Q1 Earnings: $17.55 EPS, $17.23B Revenue

Apr 13

Six Flags (SIX) Stock Price Target Cut to $29 by Guggenheim
Earnings

Six Flags (SIX) Stock Price Target Cut to $29 by Guggenheim

Apr 13

NetEase (NTES) Files Form 6K for April 13 Key Updates
Earnings

NetEase (NTES) Files Form 6K for April 13 Key Updates

Apr 13

Oklo Inc. (OKLO) Shares Fall 40% as Market Cap Drops Below $9B
Earnings

Oklo Inc. (OKLO) Shares Fall 40% as Market Cap Drops Below $9B

Apr 12